Latest Regulatory Milestones News

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

Siren Gold Limited has bolstered its leadership and financial position while delivering encouraging exploration results across its New Zealand gold and antimony projects, setting the stage for resource expansion and development progress.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

Diatreme Resources reported progress on its Northern Silica Project with key regulatory approvals and metallurgical successes, while agreeing to sell its Clermont Copper/Gold Project to Moonlight Resources, retaining a significant stake.

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.

NH3 Clean Energy has secured key government approval that streamlines regulatory processes for its WAH2 low-emissions ammonia project, keeping it on track for first production by 2026. This milestone underscores growing state support for decarbonisation initiatives in Western Australia’s strategic industrial zones.

Memphasys has signed a pivotal supply agreement with Andro Diagnostics to distribute its Felix™ sperm separation system across over 200 IVF clinics in India, marking a major step in its new global go-direct commercial strategy.

EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.

Neometals reports promising gold exploration results at Barrambie and advances lithium and vanadium projects with major partners, while completing a key business sale.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

First Au Limited has struck a deal granting AustChina Holdings an exclusive 19-month option to acquire its Eastern Victorian Goldfield Project, unlocking value from a non-core asset while sharpening focus on its African and Western Australian ventures.